AstraZeneca requests emergency use authorization for COVID-19 prophylaxis treatment

AstraZeneca today said it has requested an emergency use authorization from the Food and Drug Administration for its long-acting antibody combination for the prevention of symptomatic COVID-19. According to AstraZeneca, phase 3 trial data showed that AZD7442, when administered pre-exposure as prophylaxis, reduced the risk of developing symptomatic COVID-19 by 77%.
Related News Articles
Headline
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…
Headline
The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
The Occupational Safety and Health Administration June 30 released a proposed rule to remove what remains of its emergency temporary standard for occupational…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…
Headline
A study published April 8 by the Public Library of Science’s Journal of Global Public Health found that driving while infected with COVID-19 raises the risk of…